Novotech, the Asia-Pacific CRO, and its subsidiary Clinical Network Services (CNS) have been recognized as a top 10 CROs in the region, as well as one of the top 10 Life Science Tech Consulting/Services companies, by biopharma industry media publication Pharma Tech Outlook.
This is the second year that Novotech, the largest Asia-Pacific-based CRO, has been selected as a top 10 CRO for the region.
Novotech has been delivering CRO services in the region for more than 23 years and now has offices in 11 countries and more than 550 staff to accommodate increased demand from USA biotechs for specialist clinical services.
Dr Moller said Novotech’s growth is fueled by demand for a regional CRO with international accreditation and reputation, combined with local knowledge, partnerships and expertise.
“Novotech is focused on delivering world-class clinical services in the Asia-Pacific region for the biotech sector. We offer the very latest in Oracle and Medidata technology, and all our projects are measured on quality of service and customer satisfaction throughout every stage of our engagement,” he said.
Novotech works in partnership with the leading medical institutions across Asia to accelerate quality clinical research for its clients, and has now signed 16 strategic partnerships with hospitals and research institutions in the region.
Novotech acquired Australasian specialist CRO Clinical Network Services (CNS) as part of a mutual mission to expand services to biopharma for early phase product development and clinical research in Australia, through to later Phase regional and global trials.
Novotech’s Asia-Pacific clinical research offers:
- Large patient population
- Few competing trials
- Efficient regulatory system
- Highly qualified and educated medical professionals
- Low operational costs
- Well supported IT infrastructure
- High level of GCP compliance
- Efficient trial management and logistics infrastructure
“Our customers value our regional CRO capabilities and our local in country knowledge and leadership where we can work across and understand local cultures, customs, and regulations, and we have developed deep relationships with the key investigators in the region,” said Dr Moller.
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.
About Clinical Network Services - www.clinical.net.au
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS’ regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.
CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables CNS to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.
For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0